These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 11935432)
21. [Prognostic factors of ocular involvement in Behçet's disease]. Belkhadir K; Boutimzine N; Laghmari M; Amazouzi A; Tachfouti S; Cherkaoui O J Fr Ophtalmol; 2019 Jun; 42(6):612-617. PubMed ID: 31088739 [TBL] [Abstract][Full Text] [Related]
22. Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet's Uveitis Not Responding to Conventional Therapy. Yang P; Huang G; Du L; Ye Z; Hu K; Wang C; Qi J; Liang L; Wu L; Cao Q; Kijlstra A Ocul Immunol Inflamm; 2019; 27(1):7-14. PubMed ID: 29040035 [TBL] [Abstract][Full Text] [Related]
23. Results of interferon alpha-2a therapy in patients with Behcet's disease. Yalçindağ FN; Uzun A J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657 [TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563 [TBL] [Abstract][Full Text] [Related]
25. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease]. Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505 [TBL] [Abstract][Full Text] [Related]
26. [Clinical features of patients with Behcet's uveitis]. Liu XS; Gao F; Zhao C; Zhang MF Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):217-223. PubMed ID: 32187951 [No Abstract] [Full Text] [Related]
27. Pattern of uveitis in Behçet's disease in a referral center in Tunisia, North Africa. Khairallah M; Attia S; Yahia SB; Jenzeri S; Ghrissi R; Jelliti B; Zaouali S; Messaoud R Int Ophthalmol; 2009 Jun; 29(3):135-41. PubMed ID: 18365145 [TBL] [Abstract][Full Text] [Related]
28. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481 [TBL] [Abstract][Full Text] [Related]
38. [Ocular prognosis in Behçet's disease]. Cochereau-Massin I; Wechsler B; Le Hoang P; Le Thi Huong Du; Girard B; Rousselie F; Godeau P J Fr Ophtalmol; 1992; 15(5):343-7. PubMed ID: 1430813 [TBL] [Abstract][Full Text] [Related]
39. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease. Park JY; Chung YR; Lee K; Song JH; Lee ES Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144 [TBL] [Abstract][Full Text] [Related]
40. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease. Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Vannozzi L; Franceschini R; Bacherini D; Frediani B; Galeazzi M; Tosi GM; Cantarini L Ocul Immunol Inflamm; 2019; 27(1):58-63. PubMed ID: 28981395 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]